| Literature DB >> 34421904 |
Yu He1, Xiaoli Wang1, Jiaqi Guo1, Li Mao1, Senzhao Zhang1, Tao Hu1, Mingshu Wang1,2,3, Renyong Jia1,2,3, Dekang Zhu2,3, Mafeng Liu1,2,3, Xinxin Zhao1,2,3, Qiao Yang1,2,3, Ying Wu1,2,3, Shaqiu Zhang1,2,3, Juan Huang1,2,3, Sai Mao1,2,3, Xumin Ou1,2,3, Qun Gao1,2,3, Di Sun1,2,3, Yunya Liu1, Ling Zhang1, Yanling Yu1, Anchun Cheng1,2,3, Shun Chen1,2,3.
Abstract
Avian Tembusu virus (TMUV) is a novel flavivirus causing severe egg drop and fatal encephalitis in avian in Asia. In the present study, we screened the structural and functional requirements of TMUV capsid protein (CP) for viral morphogenesis using reverse genetics methods in combination with replicon packaging assays. TMUV-CP showed dramatic functional and structural flexibility, and even though 44 residues were removed from the N-terminus, it was still capable of packaging replicon RNA; in addition, 33 residues were deleted from the C-terminus (containing nearly the entire α4-helix), and infectious particles were still produced, although α4-α4' is supposedly vital for CP dimerization and nucleocapsid formation. We further analyzed two mutants (ΔC20-43 and ΔC64-96 viruses) with relatively large deletions that still replicated well in BHK-21 cells. Our data indicate that internal deletions within CP impaired viral replication or assembly, resulting in attenuated virus proliferation in cells and attenuated virulence in duck embryos, and these deletion mutations are quite stable in cell culture. An in vivo assay indicated that both ΔC20-43 virus and ΔC64-96 virus were highly attenuated in ducklings but still immunogenic. Single-dose immunization with ΔC20-43 virus or ΔC64-96 virus could protect ducklings from a lethal challenge with good antigen clearance. Together, our data shed light on replication/assembly defective TMUV with internal deletions in CP and provide an effective approach to attenuate viral virulence in live vaccines without changing the antigen composition.Entities:
Keywords: assembly deficient; avian Tembusu virus; capsid protein deletion; immune response; live attenuated vaccine; protective immunity; replication deficient
Mesh:
Substances:
Year: 2021 PMID: 34421904 PMCID: PMC8371329 DOI: 10.3389/fimmu.2021.694959
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 2Predicted cis-elements in capsid gene are necessary for vRNA replication. (A) The schematic diagram for a DNA based replicon expressing secretory Nluc (mC-Replicon-SecNLuc). 1-109 aa of CP and last 30 residues of E protein were retained. (B) Luciferase kinetics of mC-Replicon-SecNLuc and negative-control NS5-GDD/AAA replicon on BHK-21 cells. (C) The schematic diagram for replicons with different truncated TMUV-CPs. (D) Luciferase kinetics of replicons with different truncated CPs on BHK-21 cells. Three independent experiments are presented as means and SEM, with significance defined by P value < 0.05 (*).
Figure 3The N-terminus of TMUV-CP showed a remarkable functional flexibility. (A) The schematic diagram for mutant infectious clones with different deletions at the N-terminus to α1 of CP. (B) The viability of ΔC mutants with truncation at the N-terminus to α1, determined by IFA on BHK-21 cells. F0 viruses were generated by directly transfection with infectious clone plasmids on BHK-21 cells. (C) The schematic diagram of the DNA based packaging system. This system contains two components, the ΔC-replicon (with CP deleted, C38 means the first 38 residues of CP) expressing Nluc and the eukaryotic expression plasmid pCDNA3.1-CprM supplementing CP in trans, respectively. And the experimental designs shown in the bottom. (D) Mutant C-prM constructs used for packaging assay performed in the (E). (E) The effect of the N-terminus of CP on viral assembly, determined by packaging assay. Three independent experiments are presented as means and SEM, with significance defined by P value < 0.05 (*).
Figure 1Predicted RNA secondary structure and protein secondary structure for TMUV capsid. (A) Predicted RNA secondary structure for TMUV 1-200 nt using RNAstructure 6.0.1. The capsid gene (95-197nt) involves in SLB, 5’DAR, cHP, 5’CS and DCS-PK. (B) The results of predicted secondary for TMUV-CP, using different bioinformatics algorithms. (C) A model for TMUV-CP. TMUV-CP contains four α helices and a transmembrane helix (termed as anchor), and two mature CPs form a dimer (right).
Figure 4The α2 of TMUV-CP is less tolerated to internal deletion. (A) It depicts the mutant infectious clones with different deletions at the α2-helix of CP, and their viabilities are verified on BHK21 cells by IFA using anti-TMUV polyclonal antibody as the primary antibody (B). (C) The hydrophobic residues located at α2-helix.
Figure 5The C-terminus of TMUV-CP is responsible for vRNA binding but could tolerate large deletions. (A) The schematic diagram for mutant infectious clones with different deletions at the α3 to C-terminus of CP. (B) The viability of the ΔC mutants with deletions at the α3 to C-terminus, determined by IFA on BHK21 cells. (C)The packaging system used in the (E), eukaryotic expression plasmid pCDNA3.1-mC encoding the mature CP was used to supplements CP in trans. (D) Two clusters of basic residues located at the α4 to C-terminus. (E) Effect of these two clusters on viral assembly, determined by packaging assay. Three independent experiments are presented as means and SEM, with significance defined by P value < 0.05 (*).
Figure 6Characteristics of the ΔC20-43 virus and ΔC64-96 virus in vitro. (A) The structural models of wild-type TMUV-CP dimer, ΔC20-43 dimer and ΔC64-96 dimer. The deleted regions were indicated in white color. (B) Growth kinetics and (C) plaque morphology of the ΔC20-43 and ΔC64-96 viruses on BHK-21 cells. (D) Effect of the ΔC20-43 and ΔC64-96 deletions on virus assembly, which were determined by packaging assay on BHK-21 cells. (E) Thermostability of the ΔC20-43 and ΔC64-96 viruses. Three independent experiments are presented as means and SEM, with significance defined by P value <0.05 (*). Virulence of the ΔC20-43 and ΔC64-96 viruses in duck embryos at a dose of (F) 2,000 TCID50 or (G) 20,000 TCID50. Statistical significance of survival was analyzed using survival curve, Log-rank (Mantel-Cox) test, with significance defined by P value < 0.05 (*).
Stability of continuous passages of ΔC20-43 and ΔC64-96 on BHK-21 cells.
| ΔC20-43-F10 | ΔC64-96-F10 | ||||
|---|---|---|---|---|---|
| Location | Nucleotide Position | Amino Acid Change | Location | Nucleotide Position | Amino Acid Change |
| C | Deletion 153-224 | deletion 20-43 | C | Deletion 285-383 | deletion 64-96 |
| NS3 | A6619G, A6318C | Y537C, N577H | E | A2131G, C1809T | Q392R, H285Y |
| NS4B | C7025T | Y44* | NS1 | A2919G | K154E |
| NS4 | G9582C | G643R | NS2A | A3893G | P126* |
| NS5 | G9582C | G643R | |||
| 3’UTR | C10588T | —— | |||
*Indicates silent mutation.
Figure 7The immune responses stimulated by the ΔC20-43 and ΔC64-96 viruses. 25-day-old ducks were infected with the WT virus, ΔC20-43 and ΔC64-96 viruses at a dose of 105 TCID50, respectively. Mock group is treated with DMEM. (A) The vRNA loads in heart, liver, spleen, lung, kidney, brain and thymus of ducks were detected by RT-qPCR, at 3 dpi and 5 dpi. (B) The percentage of survival of 25-day-old ducks post infection. (C) Relative mRNA expression of IFN-α, IFN-β, TNF-α and IL-1β in the spleen were detected at 5 dpi. (D) Duck peripheral T-lymphocytes proliferative response to TMUV infection. (E) At 14 dpi, the serum levels of IFN-γ and IL-4 in the ducks were determined by ELISA. (F) Neutralization antibodies level in the serum were determined by PRNT. Data are presented as means and SEM, with significance defined by P value < 0.05 (*), ns means no significance.
Figure 8Single-dose immunization of the ΔC20-43 and ΔC64-96 viruses protected ducklings from lethal challenge by an epidemic TMUV. (A) Experimental design for animal experiment. 5-day-old ducklings were intramuscularly injected with the WT virus, ΔC20-43 and ΔC64-96 mutant viruses at a dose of 105 TCID50, respectively. Mock group is treated with DMEM. At 14 days post immunization, survival ducklings were challenged with a virulent TMUV. (B) Weight change post immunization (days 1-14) and post challenge (days 15-28). (C) Viremia post immunization. (D) Clinical symptoms post immunization. In each item, 1 score corresponding to 1 duck appear symptom. The total points= 20% * item 1 + 30% * item 2 + 50% * item 3. (E) Percentage of survival post immunization. (F) Viremia post challenge. (G) Clinical symptoms post challenge. (H) Percentage of survival post challenge.